Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...6364656667686970717273...136137»
  • ||||||||||  leflunomide / Generic mfg., azathioprine / Generic mfg.
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy (clinicaltrials.gov) -  Apr 14, 2022   
    P3,  N=290, Completed, 
    Intensified monitoring with emphasis on the prevention of infectious complications could be of value to prevent uncontrolled disease in MG patients. Recruiting --> Completed | N=158 --> 290 | Trial completion date: Jun 2020 --> Nov 2021 | Trial primary completion date: Dec 2019 --> Oct 2021
  • ||||||||||  Review, Journal:  Outcomes of extended surgical resections for locally advanced thymic malignancies: a narrative review. (Pubmed Central) -  Apr 12, 2022   
    In this narrative review, we describe indications and surgical techniques for the treatment of locally advanced thymoma; focusing on oncological outcomes after different approaches. In conclusion, aggressive surgery is always indicated, when possible, and when a complete resection can be planned, yet, the multidisciplinary approach is mandatory, in case of both locally or metastatic advanced disease.
  • ||||||||||  Review, Journal:  Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective. (Pubmed Central) -  Apr 9, 2022   
    This review covers the following conditions as models and highlight those in which a relationship with COVID-19 infection has been reported: a) Acute Necrotizing Encephalopathy; b) Measles-associated encephalopathies; c) Human Immunodeficiency Virus (HIV) neuroimmune disorders, and particularly the difficulties associated with classical post-infectious autoimmune disorders such as the Guillain-Barré syndrome in the context of HIV and other infections. Finally, we describe NMDA-R encephalitis, which can be post-HSV encephalitis, summarise other antibody-mediated CNS diseases and describe myasthenia gravis as the classic antibody-mediated disease but with special features in Africa.
  • ||||||||||  Immune-related neurological disorders in patients with renal and bladder cancer (B7) -  Apr 9, 2022 - Abstract #EAN2022EAN_1198;    
    PNS associated to RCC or BC are rare and the nature of neurological disorders linked to these cancers remains controversial. Even though n-irAEs after ICI are more commonly expected in these tumors, they do not probably respond to a paraneoplastic mechanism in most cases.
  • ||||||||||  B cell related predictive biomarkers of treatment response in myasthenia gravis (B8) -  Apr 9, 2022 - Abstract #EAN2022EAN_879;    
    The persistence of transitional B-cells, rather than antigen experienced B-cells, might predict unresponsiveness to immunotherapy in a subgroup of patients. In these cases, early B cell-directed therapies could restore the balance between regulatory and inflammatory B-cells in the pre-germinal compartment.
  • ||||||||||  atorvastatin / Generic mfg., azathioprine / Generic mfg.
    Effect of statin use on severity of late onset myasthenia gravis (B7) -  Apr 9, 2022 - Abstract #EAN2022EAN_811;    
    However, the study was limited by the number of patients and prescribed dosage of statins. We plan to continue the study with a larger sample of patients.
  • ||||||||||  Sleep quality of myasthenia gravis patients during the coronavirus disease-19 pandemic (A1) -  Apr 9, 2022 - Abstract #EAN2022EAN_712;    
    The ongoing Vivacity MG Phase 3 study will assess the efficacy, safety, and PK/PD of Nipocalimab in adult gMG. Lower levels of QoS correlate with worse life quality, some clinical and socio-demographic variables in MG patients, especially with higher disease severity.
  • ||||||||||  zilucoplan (RA101495) / UCB
    Zilucoplan prevented functional impairment induced by AChR+ myasthenia gravis patient sera in an in vitro NMJ model (B7) -  Apr 9, 2022 - Abstract #EAN2022EAN_693;    
    Lower levels of QoS correlate with worse life quality, some clinical and socio-demographic variables in MG patients, especially with higher disease severity. These data provide a mechanistic rationale for the clinical response observed in AChR+ gMG patients treated with C5 inhibitors and highlight how an in vitro human NMJ platform may functionally dissect pathogenic autoantibodies and support drug discovery.
  • ||||||||||  Effectiveness of early treatment initiation with corticosteroids in Ocular Myasthenia Gravis (B7) -  Apr 9, 2022 - Abstract #EAN2022EAN_692;    
    These data provide a mechanistic rationale for the clinical response observed in AChR+ gMG patients treated with C5 inhibitors and highlight how an in vitro human NMJ platform may functionally dissect pathogenic autoantibodies and support drug discovery. Our suggested approach consisting of early and adequate immunotherapy in OMG patients significantly reduced the risk of generalization, allowed better control of generalized symptoms when present and resulted in less residual ocular symptoms.
  • ||||||||||  Ultomiris IV (ravulizumab IV) / AstraZeneca
    Ravulizumab Reduces Clinical Deteriorations in Patients with Generalised Myasthenia Gravis (Room Helsinki) -  Apr 9, 2022 - Abstract #EAN2022EAN_271;    
    P3
    Ravulizumab treatment was associated with numerically fewer clinical-deterioration events compared with placebo. These findings support the efficacy of ravulizumab in controlling acute worsening of symptoms in patients with AChR Ab+ gMG.
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Long-term Safety and Efficacy of Efgartigimod in Patients With Generalised Myasthenia Gravis (Room Helsinki) -  Apr 9, 2022 - Abstract #EAN2022EAN_272;    
    These findings support the efficacy of ravulizumab in controlling acute worsening of symptoms in patients with AChR Ab+ gMG. The results of these analyses suggest long-term treatment with efgartigimod was well tolerated and efficacious.
  • ||||||||||  Journal:  Thyrotoxic myopathy: research status, diagnosis, and treatment. (Pubmed Central) -  Apr 8, 2022   
    Given the clinical characteristics, thyrotoxic myopathy can be devided into chronic thyrotoxic myopathy, thyrotoxicosis with periodic paralysis, acute thyrotoxic myopathy, hyperthyroidism with myasthenia gravis, as well as infiltrating exophthalmos with ophthalmoplegia. In this paper, we review thyrotoxic myopathy research status, diagnoses, and treatments.
  • ||||||||||  Review, Journal:  Thymolipomatous myasthenia gravis outcomes following thymectomy: a systematic review. (Pubmed Central) -  Apr 8, 2022   
    We found a significant statistical difference between the 2 groups in terms of age, because younger patients tended to improve to a greater degree post-thymectomy. Also, we found that female patients with thymoma visible on the imaging scans were significantly associated with post-thymectomy myasthenia gravis improvement.
  • ||||||||||  Biomarker, Clinical, Observational data, Retrospective data, Review, Journal:  Amino acids levels as a potential biomarker in myasthenia gravis. (Pubmed Central) -  Apr 8, 2022   
    Moreover, our preliminary results suggest that the metabolism of some amino acids seems to be changed in patients with MG. Therefore, we conclude that amino acids profiling might be helpful in searching for putative biomarkers of the central nervous system diseases such as myasthenia gravis.
  • ||||||||||  Journal:  Myasthenia Gravis and Pregnancy: Toronto Specialty Centre Experience. (Pubmed Central) -  Apr 7, 2022   
    The gender distribution, age of onset, pharmacological characteristics and electrophysiological examination of DP-MG patients were similar to those of MuSK-MG patients, but the severity of DP-MG patients was between that of AChR-MG and MuSK-MG patients. No abstract available
  • ||||||||||  Clinical, Journal:  Low Vitamin D Serum Levels in a Cohort of Myasthenia Gravis Patients in Argentina. (Pubmed Central) -  Apr 7, 2022   
    However, when we compared 25(OH)D median serum levels between MG patients and HV, no statistically significant differences have been found. This is the first report of vitD status in a cohort of Argentinean MG patients, where we found that patients are more likely to have non-sufficient levels of vitD compared to healthy people and that patients with more severe disease have lower levels of vitD.